Mads Agerbæk

6.3k total citations
98 papers, 2.6k citations indexed

About

Mads Agerbæk is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Mads Agerbæk has authored 98 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Surgery, 35 papers in Pulmonary and Respiratory Medicine and 26 papers in Oncology. Recurrent topics in Mads Agerbæk's work include Bladder and Urothelial Cancer Treatments (44 papers), Testicular diseases and treatments (30 papers) and Urinary and Genital Oncology Studies (19 papers). Mads Agerbæk is often cited by papers focused on Bladder and Urothelial Cancer Treatments (44 papers), Testicular diseases and treatments (30 papers) and Urinary and Genital Oncology Studies (19 papers). Mads Agerbæk collaborates with scholars based in Denmark, United States and Netherlands. Mads Agerbæk's co-authors include Lars Dyrskjøt, Iver Nordentoft, Gedske Daugaard, Karin Birkenkamp‐Demtröder, Jakob Lauritsen, Jørgen Bjerggaard Jensen, Niels V. Holm, Emil Christensen, Mette Saksø Mortensen and Bjørn Richelsen and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mads Agerbæk

91 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mads Agerbæk Denmark	28	1.6k	836	788	483	447	98	2.6k
Yoav H. Messinger United States	32	1.7k 1.1×	1.2k 1.5×	844 1.1×	289 0.6×	359 0.8×	106	3.5k
Francesca Sanguedolce Italy	28	701 0.5×	744 0.9×	700 0.9×	338 0.7×	547 1.2×	167	2.3k
Sophie Ferlicot France	29	628 0.4×	825 1.0×	902 1.1×	369 0.8×	454 1.0×	124	2.5k
Takaharu Oue Japan	29	1.2k 0.8×	768 0.9×	732 0.9×	258 0.5×	408 0.9×	145	2.5k
Axel Hegele Germany	23	671 0.4×	709 0.8×	600 0.8×	246 0.5×	409 0.9×	134	1.9k
Yoshiaki Tsuchida Japan	28	1.3k 0.8×	593 0.7×	691 0.9×	276 0.6×	276 0.6×	122	2.4k
Kutsal Yörükoğlu Türkiye	22	511 0.3×	596 0.7×	459 0.6×	195 0.4×	269 0.6×	144	1.6k
W. David J. Ryder United Kingdom	30	731 0.5×	995 1.2×	623 0.8×	357 0.7×	1.3k 3.0×	64	3.1k
Steen Werner Hansen Denmark	20	2.0k 1.3×	583 0.7×	641 0.8×	132 0.3×	993 2.2×	45	3.1k
Guido Seitz Germany	24	681 0.4×	907 1.1×	530 0.7×	246 0.5×	380 0.9×	138	2.1k

Countries citing papers authored by Mads Agerbæk

Since Specialization

Citations

This map shows the geographic impact of Mads Agerbæk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mads Agerbæk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mads Agerbæk more than expected).

Fields of papers citing papers by Mads Agerbæk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mads Agerbæk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mads Agerbæk. The network helps show where Mads Agerbæk may publish in the future.

Co-authorship network of co-authors of Mads Agerbæk

This figure shows the co-authorship network connecting the top 25 collaborators of Mads Agerbæk. A scholar is included among the top collaborators of Mads Agerbæk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mads Agerbæk. Mads Agerbæk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nørgaard, Mette, et al.. (2025). Treatment patterns in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2023 – an updated analysis. Acta Oncologica. 64. 630–632.

Galsky, Matthew D., Dean F. Bajorin, Yoshihiko Tomita, et al.. (2025). Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. Nature Medicine. 31(9). 3062–3073.

Schenker, Michael, Begoña P. Valderrama, A. Bamias, et al.. (2025). 3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Annals of Oncology. 36. S1482–S1482.

Juul, Randi Istrup, Iver Nordentoft, Karin Birkenkamp‐Demtröder, et al.. (2025). Low T cell diversity associates with poor outcome in bladder cancer: A comprehensive longitudinal analysis of the T cell receptor repertoire. Cell Reports Medicine. 6(5). 102101–102101. 1 indexed citations

Jensen, Jørgen Bjerggaard, Karin Birkenkamp‐Demtröder, Iver Nordentoft, et al.. (2024). 1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial. Annals of Oncology. 35. S1133–S1133. 15 indexed citations

Tolbod, Lars Poulsen, Bodil Ginnerup Pedersen, Thierry N. Boellaard, et al.. (2024). [15O]H2O PET/MRI for Assessment of Complete Response to Neoadjuvant or Induction Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Pilot Study. Journal of Clinical Medicine. 13(16). 4652–4652.

Daugaard, Gedske, Mikkel Bandak, Mads Agerbæk, et al.. (2024). Use of Risk Factors To Select Adjuvant Therapy Versus Surveillance for Testicular Nonseminoma and Seminoma Germ Cell Tumors. European Urology Focus. 10(3). 359–360. 1 indexed citations

Christensen, Emil, Iver Nordentoft, Karin Birkenkamp‐Demtröder, et al.. (2023). Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 29(8). 1582–1591. 36 indexed citations

Nørgaard, Mette, et al.. (2023). Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015–2020. Acta Oncologica. 62(12). 1784–1790. 3 indexed citations

10.

Lindskrog, Sia V., Karin Birkenkamp‐Demtröder, Iver Nordentoft, et al.. (2023). Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clinical Cancer Research. 29(23). 4797–4807. 26 indexed citations

11.

Wagner, Thomas, Birgitte Grønkær Toft, Jakob Lauritsen, et al.. (2023). Prognostic factors for relapse in patients with clinical stage I testicular seminoma: A nationwide, population-based cohort study.. Journal of Clinical Oncology. 41(16_suppl). 5041–5041. 1 indexed citations

12.

Bajorin, Dean F., J. Alfred Witjes, Jürgen E. Gschwend, et al.. (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. 39(6_suppl). 391–391. 30 indexed citations

13.

Sørup, Signe, Bianka Darvalics, Azza A. Khalil, et al.. (2021). Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. Clinical Epidemiology. Volume 13. 871–882. 1 indexed citations

14.

Als, Anne Birgitte, Mads Agerbæk, Henriette Lindberg, et al.. (2021). Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen. Bladder Cancer. 8(1). 71–80. 4 indexed citations

15.

Zachariae, Robert, et al.. (2021). Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in newly orchiectomized testicular cancer patients. Brain Imaging and Behavior. 16(1). 199–210. 11 indexed citations

16.

Lauritsen, Jakob, Mikkel Bandak, Michael Kreiberg, et al.. (2020). Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study. Journal of Cancer Survivorship. 15(4). 509–517. 17 indexed citations

17.

Tanderup, Kari, et al.. (2016). Successful treatment of a 67-year-old woman with urethral adenocarcinoma with the use of external beam radiotherapy and image guided adaptive interstitial brachytherapy. Journal of Contemporary Brachytherapy. 5(5). 434–437. 1 indexed citations

18.

Lauritsen, Jakob, Mette Saksø Mortensen, M.G.G. Kier, et al.. (2014). Renal impairment and late toxicity in germ-cell cancer survivors. Annals of Oncology. 26(1). 173–178. 26 indexed citations

19.

Fode, Kirsten, et al.. (2013). Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma. Journal of Oral and Maxillofacial Surgery. 71(9). 1532–1540. 53 indexed citations

20.

Agerbæk, Mads, Jan Alsner, Niels Marcussen, Finn Lundbeck, & Hans von der Maase. (2003). Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. British Journal of Cancer. 89(2). 298–304. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact